Magnus Essand
- Mobile phone:
- +46 70 344 95 79
- E-mail:
- magnus.essand@igp.uu.se
- Visiting address:
- Dag Hammarskjölds väg 20
751 85 Uppsala - Postal address:
- Rudbecklaboratoriet
751 85 UPPSALA
- CV:
- Download CV
Short presentation
Essand obtained his PhD in 1995 and received four years of postdoctoral training at the National Cancer Institute. He returned to Sweden as an Associate Professor in Immunology in 2000 and became Professor in Gene Therapy in 2009.
Essand has tutored 13 PhDs and published more than 100 original research articles.
Essand is the sponsor and scientific lead in clinical trials on gene and cell therapy products developed in his laboratory, including CAR-T cells and oncolytic viruses.
Keywords
- • Cancer immunotherapy • CAR-T cell • Epitope spread • Tumor microenvironment • Oncolytic virus • AAV vectors
Biography
10 Selected Senior Authorship Publications
- Barbera S, Schuiling MJA, Sanjaya NA, Pietilä I, Sarén T, Essand M*, Dimberg A*. Trogocytosis of Chimeric Antigen Receptors between T cells is regulated by their transmembrane domains. Science Immunology, 10: eado2054, 2025. ME and AD are shared senior authors. (Impact Factor 17.6)
- Martikainen M, Lugano R, Pietilä I, Brosch S, Cabrolier C, Sivaramakrishnam A, Ramachandran M, Yu D, Dimberg A, Essand M. VLDLR mediates Semliki Forest virus neuroinvasion through the blood-cerebrospinal fluid barrier. Nature Communications, 15:10718, 2024.
- Sarén T#, Ramachandran M#, Gammelgård G, Lövgren T, Mirabello C, Björklund ÅK, Wikström K, Hashemi J, Freyhult E, Ahlström H, Amini R-M, Hagberg H, Loskog A, Enblad G*, Essand M*. Single-cell RNA analysis reveals cell-intrinsic functions of CAR-T-cells correlating with response in a phase II study of lymphoma patients. Clinical Cancer Research, 29:4139, 2023. TS and MR are shared first authors; GE and ME are shared senior authors. (Impact Factor 13.8)
- Sarén T, Saronio G, Marti-Torell P, Zhu X, Thelander J, Andersson Y, Hofström C, Nestor M, Dimberg A, Persson H, Ramachandran M, Yu D*, EssandM*. Complementarity-determining region clustering may cause CAR-T cell dysfunction. Nature Communications, 14:4732, 2023. DY and ME are shared senior authors. (Impact Factor 17.7)
- Ramachandran M#, Vaccaro A#, van de Walle T#, Georganaki M, Lugano, R, Vemuri, K, Kourougkiaouri D, Vazaios K, Hedlund M, Tsaridou G, Uhrbom L, Pietilä I, Martikainen M, Van Hooren L, Olsson Bontell T, Jakola AS, Yu D, Westermark B, Essand M*, Dimberg A*. Tailoring vascular phenotype through AAV therapy promotes anti-tumor immunity in glioma. Cancer Cell, 41:1134, 2023. ME and AD are shared senior authors. (Impact Factor 50.3).
- Jin C#, Ma J#, Ramachandran M, Yu D*, Essand M*. CAR T cells expressing a bacterial virulence factor trigger potent bystander antitumour responses in solid cancers. Nature Biomedical Engineering, 6:830, 2022. DY and ME are shared senior authors (Impact Factor 29.2)
- Ma J#, Ramachandran M, # Jin C#, Quijano-Rubio, Martikainen M, Yu D*, Essand M*. Characterization of virus-mediated immunogenic cancer cell death and the consequences for oncolytic virus-based immunotherapy of cancer. Cell Death & Disease 11: 48, 2020. JM, MR and CJ are shared first authors; DY and ME are shared senior authors
- Ramachandran M#, Yu D#, Dyczynski M, Baskaran S, Nelander S, Zhang L, Lulla A, Lulla V, Saul S, Dimberg A, Merits A, Leja-Jarblad J, Essand M. Safe and effective treatment of experimental neuroblastoma and glioblastoma using systemically administered triple microRNA-detargeted oncolytic Semliki Forest virus. Clinical Cancer Research, 23: 1519-1530, 2017. MR and DY are shared first authors
- Jin C, Fotaki G, Ramachandran M, Nilsson B, Essand M*, Yu D*. Safe engineering of CAR T cells for adoptive cell therapy of cancer using long-term episomal gene transfer. EMBO Molecular Medicine, 8: 702-11, 2016. ME and DY are shared senior authors
- Hillerdal V, Nilsson B, Carlsson B, Eriksson F, Essand M. TARP-TCR-engineered T cells specifically kill HLA-A2 positive prostate and breast cancer cells. Proc Natl Acad Sci USA, 109:15877-15881, 2012.
Research
Immunotherapy has during the last decades proven to be effective and gained a strong position in clinical oncology. Although tremendous achievements have been made, we have only just begun the work to understand how immune regulatory mechanisms in cancer can be exploited for treatment.
Our research programs aim to understand the mechanisms that make cancer cells escape immune recognition and use this knowledge to develop new and better immunotherapies. We create innovative chimeric antigen receptor (CAR)-T cells, oncolytic viruses and viral vectors and arm them with factors that can increase T cell recruitment and induce potent anti-tumor immune responses. To address antigen heterogeneity within solid tumors, we strive to develop immunotherapy products that can induce epitope spread and activate endogenous tumor antigen-specific cytolytic T cells.
We combine pre-clinical research with translational studies. CAR-T cells and oncolytic viruses developed in the research group are currently being evaluated in clinical trials at Uppsala University Hospital. We are continuously developing more sophisticated gene and cell therapy products, and we anticipate that our novel therapies will enter clinical trials within the coming years.

Publications
Recent publications
-
News from the T cell trogocytosis front
Part of Trends in immunology, p. 677-689, 2025
- DOI for News from the T cell trogocytosis front
- Download full text (pdf) of News from the T cell trogocytosis front
-
Part of Cancer Immunology and Immunotherapy, 2025
- DOI for Pre-clinical safety and efficacy evaluation of Helicobacter Pylori neutrophil-activating protein (NAP)-armed CAR-T cells targeting B cell lymphomas
- Download full text (pdf) of Pre-clinical safety and efficacy evaluation of Helicobacter Pylori neutrophil-activating protein (NAP)-armed CAR-T cells targeting B cell lymphomas
-
Part of Science immunology, 2025
-
Immunotherapy for Neuroendocrine Neoplasms
Part of Neuroendocrine Tumours, p. 665-676, Springer Nature, 2024
-
Part of Genetic Engineering and Biotechnology News, p. 42-43, 2024
All publications
Articles in journal
-
Part of Cancer Immunology and Immunotherapy, 2025
- DOI for Pre-clinical safety and efficacy evaluation of Helicobacter Pylori neutrophil-activating protein (NAP)-armed CAR-T cells targeting B cell lymphomas
- Download full text (pdf) of Pre-clinical safety and efficacy evaluation of Helicobacter Pylori neutrophil-activating protein (NAP)-armed CAR-T cells targeting B cell lymphomas
-
Part of Science immunology, 2025
-
Part of Genetic Engineering and Biotechnology News, p. 42-43, 2024
-
VLDLR mediates Semliki Forest virus neuroinvasion through the blood-cerebrospinal fluid barrier
Part of Nature Communications, 2024
- DOI for VLDLR mediates Semliki Forest virus neuroinvasion through the blood-cerebrospinal fluid barrier
- Download full text (pdf) of VLDLR mediates Semliki Forest virus neuroinvasion through the blood-cerebrospinal fluid barrier
-
Part of Molecular Therapy Nucleic Acids, 2024
- DOI for Targeting ZC3H11A elicits immunogenic cancer cell death through augmentation of antigen presentation and interferon response
- Download full text (pdf) of Targeting ZC3H11A elicits immunogenic cancer cell death through augmentation of antigen presentation and interferon response
-
Enhanced Cellular Uptake through Nanotopography-Induced Macropinocytosis
Part of Advanced Functional Materials, 2024
- DOI for Enhanced Cellular Uptake through Nanotopography-Induced Macropinocytosis
- Download full text (pdf) of Enhanced Cellular Uptake through Nanotopography-Induced Macropinocytosis
-
Tailoring vascular phenotype through AAV therapy promotes anti-tumor immunity in glioma
Part of Cancer Cell, p. 1134-1151, 2023
- DOI for Tailoring vascular phenotype through AAV therapy promotes anti-tumor immunity in glioma
- Download full text (pdf) of Tailoring vascular phenotype through AAV therapy promotes anti-tumor immunity in glioma
-
Part of Clinical Cancer Research, p. 4139-4152, 2023
- DOI for Single-Cell RNA Analysis Reveals Cell-Intrinsic Functions of CAR T Cells Correlating with Response in a Phase II Study of Lymphoma Patients
- Download full text (pdf) of Single-Cell RNA Analysis Reveals Cell-Intrinsic Functions of CAR T Cells Correlating with Response in a Phase II Study of Lymphoma Patients
-
CD4+ T cell-induced inflammatory cell death controls immune-evasive tumours
Part of Nature, p. 1033-1040, 2023
- DOI for CD4+ T cell-induced inflammatory cell death controls immune-evasive tumours
- Download full text (pdf) of CD4+ T cell-induced inflammatory cell death controls immune-evasive tumours
-
Complementarity-determining region clustering may cause CAR-T cell dysfunction
Part of Nature Communications, 2023
- DOI for Complementarity-determining region clustering may cause CAR-T cell dysfunction
- Download full text (pdf) of Complementarity-determining region clustering may cause CAR-T cell dysfunction
-
Part of Molecular Therapy Nucleic Acids, p. 450-461, 2022
- DOI for CRISPR-Cas9 treatment partially restores amyloid-β 42/40 in human fibroblasts with the Alzheimer's disease PSEN1 M146L mutation
- Download full text (pdf) of CRISPR-Cas9 treatment partially restores amyloid-β 42/40 in human fibroblasts with the Alzheimer's disease PSEN1 M146L mutation
-
Part of Oncoimmunology, 2022
- DOI for Intratumoral administration of pro-inflammatory allogeneic dendritic cells improved the anti-turnor response of systemic anti-CTLA-4 treatment via unleashing a T cell-dependent response
- Download full text (pdf) of Intratumoral administration of pro-inflammatory allogeneic dendritic cells improved the anti-turnor response of systemic anti-CTLA-4 treatment via unleashing a T cell-dependent response
-
ZC3H11A loss of function enhances NF-κB signaling through defective IκBα protein expression
Part of Frontiers in Immunology, 2022
- DOI for ZC3H11A loss of function enhances NF-κB signaling through defective IκBα protein expression
- Download full text (pdf) of ZC3H11A loss of function enhances NF-κB signaling through defective IκBα protein expression
-
Targeting circulating monocytes with CCL2-loaded liposomes armed with an oncolytic adenovirus
Part of Nanomedicine, 2022
-
Part of Cancer Imaging, 2022
- DOI for Whole body FDG PET/MR for progression free and overall survival prediction in patients with relapsed/refractory large B-cell lymphomas undergoing CAR T-cell therapy
- Download full text (pdf) of Whole body FDG PET/MR for progression free and overall survival prediction in patients with relapsed/refractory large B-cell lymphomas undergoing CAR T-cell therapy
-
Ixovex-1, a novel oncolytic E1B-mutated adenovirus
Part of Cancer Gene Therapy, p. 1628-1635, 2022
- DOI for Ixovex-1, a novel oncolytic E1B-mutated adenovirus
- Download full text (pdf) of Ixovex-1, a novel oncolytic E1B-mutated adenovirus
-
Part of Nature Biomedical Engineering, p. 830-841, 2022
- DOI for CAR T cells expressing a bacterial virulence factor trigger potent bystander antitumour responses in solid cancers
- Download full text (pdf) of CAR T cells expressing a bacterial virulence factor trigger potent bystander antitumour responses in solid cancers
-
Part of Nanomaterials, 2021
- DOI for Development of a New Hyaluronic Acid Based Redox-Responsive Nanohydrogel for the Encapsulation of Oncolytic Viruses for Cancer Immunotherapy
- Download full text (pdf) of Development of a New Hyaluronic Acid Based Redox-Responsive Nanohydrogel for the Encapsulation of Oncolytic Viruses for Cancer Immunotherapy
-
Part of Nature Communications, 2021
- DOI for Agonistic CD40 therapy induces tertiary lymphoid structures but impairs responses to checkpoint blockade in glioma
- Download full text (pdf) of Agonistic CD40 therapy induces tertiary lymphoid structures but impairs responses to checkpoint blockade in glioma
-
Part of MOLECULAR THERAPY-ONCOLYTICS, p. 37-46, 2021
- DOI for IFN-I-tolerant oncolytic Semliki Forest virus in combination with anti-PD1 enhances T cell response against mouse glioma
- Download full text (pdf) of IFN-I-tolerant oncolytic Semliki Forest virus in combination with anti-PD1 enhances T cell response against mouse glioma
-
Perivascular macrophages regulate blood flow following tissue damage
Part of Circulation Research, p. 1694-1707, 2021
-
Part of Cell Death and Disease, 2020
- DOI for Characterization of virus-mediated immunogenic cancer cell death and the consequences for oncolytic virus-based immunotherapy of cancer
- Download full text (pdf) of Characterization of virus-mediated immunogenic cancer cell death and the consequences for oncolytic virus-based immunotherapy of cancer
-
Astrocytes have the capacity to act as antigen-presenting cells in the Parkinson's disease brain
Part of Journal of Neuroinflammation, 2020
- DOI for Astrocytes have the capacity to act as antigen-presenting cells in the Parkinson's disease brain
- Download full text (pdf) of Astrocytes have the capacity to act as antigen-presenting cells in the Parkinson's disease brain
-
Part of Haematologica, p. 1306-1316, 2020
- DOI for TARP is an immunotherapeutic target in acute myeloid leukemia expressed in the leukemic stem cell compartment
- Download full text (pdf) of TARP is an immunotherapeutic target in acute myeloid leukemia expressed in the leukemic stem cell compartment
-
Part of Oncoimmunology, 2020
- DOI for Tumor endothelial cell up-regulation of IDO1 is an immunosuppressive feed-back mechanism that reduces the response to CD40-stimulating immunotherapy
- Download full text (pdf) of Tumor endothelial cell up-regulation of IDO1 is an immunosuppressive feed-back mechanism that reduces the response to CD40-stimulating immunotherapy
-
Part of Journal of Pathology, p. 228-240, 2019
-
Part of Cell Stem Cell, p. 855-870, 2019
- DOI for Humanized Stem Cell Models of Pediatric Medulloblastoma Reveal an Oct4/mTOR Axis that Promotes Malignancy
- Download full text (pdf) of Humanized Stem Cell Models of Pediatric Medulloblastoma Reveal an Oct4/mTOR Axis that Promotes Malignancy
-
CD93 promotes β1 integrin activation and fibronectin fibrillogenesis during tumor angiogenesis
Part of Journal of Clinical Investigation, p. 3280-3297, 2018
- DOI for CD93 promotes β1 integrin activation and fibronectin fibrillogenesis during tumor angiogenesis
- Download full text (pdf) of CD93 promotes β1 integrin activation and fibronectin fibrillogenesis during tumor angiogenesis
-
Part of Molecular Cancer Therapeutics, p. 1961-1972, 2018
- DOI for Leukocyte differentiation by histidine-rich glycoprotein/stanniocalcin-2 complex regulates murine glioma growth through modulation of anti-tumor immunity
- Download full text (pdf) of Leukocyte differentiation by histidine-rich glycoprotein/stanniocalcin-2 complex regulates murine glioma growth through modulation of anti-tumor immunity
-
A Phase I/IIa Trial Using CD19-Targeted Third-Generation CAR T Cells for Lymphoma and Leukemia
Part of Clinical Cancer Research, p. 6185-6194, 2018
-
Part of Oncoimmunology, 2018
-
Part of Oncoimmunology, 2018
- DOI for Cancer vaccine based on a combination of an infection-enhanced adenoviral vector and pro-inflammatory allogeneic DCs leads to sustained antigen-specific immune responses in three melanoma models
- Download full text (pdf) of Cancer vaccine based on a combination of an infection-enhanced adenoviral vector and pro-inflammatory allogeneic DCs leads to sustained antigen-specific immune responses in three melanoma models
-
Part of Experimental dermatology, 2018
-
Perivascular macrophages regulate blood flow following tissue damage
Part of European Journal of Clinical Investigation, p. 44-45, 2018
-
Multiple nuclear-replicating viruses require the stress-induced protein ZC3H11A for efficient growth
Part of Proceedings of the National Academy of Sciences of the United States of America, 2018
-
Part of Clinical Cancer Research, p. 1519-1530, 2017
-
Part of Neuroendocrinology, p. 54-66, 2017
-
Immunological biomarkers correlate to survival in CAR19-treated patients
Part of Scandinavian Journal of Immunology, p. 337-337, 2017
-
Part of Scandinavian Journal of Immunology, p. 341-341, 2017
-
Part of Molecular Therapy, p. 288-288, 2017
-
Part of British Journal of Cancer, p. 51-55, 2017
-
PATZ1 down-regulates FADS1 by binding to rs174557 and is opposed by SP1/SREBP1c
Part of Nucleic Acids Research, p. 2408-2422, 2017
-
Part of Neuroendocrinology, p. 115-115, 2016
-
Avidity characterization of genetically engineered T-cells with novel and established approaches
Part of BMC Immunology, 2016
- DOI for Avidity characterization of genetically engineered T-cells with novel and established approaches
- Download full text (pdf) of Avidity characterization of genetically engineered T-cells with novel and established approaches
-
Part of Virology, p. 44-50, 2016
-
Heparanase Promotes Glioma Progression and is Inversely Correlated with Patient Survival.
Part of Molecular Cancer Research, p. 1243-1253, 2016
-
Prospects to improve chimeric antigen receptor T-cell therapy for solid tumors
Part of Immunotherapy, p. 1355-1361, 2016
-
Part of CANCER IMMUNOLOGY RESEARCH, 2016
-
Long-term episomal gene transfer for safe engineering of T cells for adoptive cell therapy of cancer
Part of CANCER IMMUNOLOGY RESEARCH, 2016
-
Part of CANCER IMMUNOLOGY RESEARCH, 2016
-
Part of EMBO Molecular Medicine, p. 702-711, 2016
- DOI for Safe engineering of CAR T cells for adoptive cell therapy of cancer using long-term episomal gene transfer
- Download full text (pdf) of Safe engineering of CAR T cells for adoptive cell therapy of cancer using long-term episomal gene transfer
-
Part of Molecular Therapy, 2016
-
Part of Cancer Research, p. 4504-4516, 2015
-
Part of Cell Transplantation, p. 263-276, 2015
-
Part of Science Signaling, 2015
-
Part of Cell Transplantation, p. 263-276, 2015
-
Chimeric Antigen Receptor-Engineered T Cells for the Treatment of Metastatic Prostate Cancer
Part of BioDrugs, p. 75-89, 2015
- DOI for Chimeric Antigen Receptor-Engineered T Cells for the Treatment of Metastatic Prostate Cancer
- Download full text (pdf) of Chimeric Antigen Receptor-Engineered T Cells for the Treatment of Metastatic Prostate Cancer
-
Part of Blood, 2015
-
Part of Regenerative Medicine Research, 2015
- DOI for Mesenchymal stromal cells supportendothelial cell interactions in anintramuscular islet transplantation model
- Download full text (pdf) of Mesenchymal stromal cells supportendothelial cell interactions in anintramuscular islet transplantation model
-
Part of The FASEB Journal, 2014
-
Preclinical Safety Assessment of Ad[I/PPT-E1A], a Novel Oncolytic Adenovirus for Prostate Cancer
Part of Human Gene Therapy Clinical Development, p. 7-15, 2014
-
Long-term episomal gene transfer for safe engineering of T-cells for adoptive cell therapy of cancer
Part of Human Gene Therapy, 2014
-
Part of BMC Cancer, p. 30, 2014
- DOI for Systemic treatment with CAR-engineered T cells against PSCA delays subcutaneous tumor growth and prolongs survival of mice
- Download full text (pdf) of Systemic treatment with CAR-engineered T cells against PSCA delays subcutaneous tumor growth and prolongs survival of mice
-
Part of Molecular Therapy, 2014
-
Part of Journal of immunotherapy (1997), p. 155-162, 2014
-
Part of Molecular Therapy Methods & Clinical Development, 2014
-
Part of Journal of Immunology, p. 2287-2296, 2014
-
Histidine-Rich Glycoprotein (HRG): A Novel Gene-Therapy Effector for the Treatment of Cancer
Part of Molecular Therapy, 2014
-
Part of Molecular Therapy, 2014
-
Engineering Regulatory Cells With a T Cell Receptor for Controlled Activation
Part of Molecular Therapy, 2014
-
Part of Molecular Therapy, p. 2008-2018, 2013
- DOI for An infection-enhanced oncolytic adenovirus secreting H. pylori neutrophil-activating protein with therapeutic effects on neuroendocrine tumors
- Download full text (pdf) of An infection-enhanced oncolytic adenovirus secreting H. pylori neutrophil-activating protein with therapeutic effects on neuroendocrine tumors
-
Virotherapy of Neuroendocrine Tumors
Part of Neuroendocrinology, p. 26-34, 2013
-
Part of PLOS ONE, 2013
- DOI for Adenovirus Serotype 5 Vectors with Tat-PTD Modified Hexon and Serotype 35 Fiber Show Greatly Enhanced Transduction Capacity of Primary Cell Cultures
- Download full text (pdf) of Adenovirus Serotype 5 Vectors with Tat-PTD Modified Hexon and Serotype 35 Fiber Show Greatly Enhanced Transduction Capacity of Primary Cell Cultures
-
Part of Cancer Gene Therapy, p. 386-393, 2013
-
Part of European Journal of Clinical Investigation, p. 27-27, 2013
-
Histidine-Rich Glycoprotein (HRG): A Novel Gene-Therapy Effector for the Treatment of Cancer
Part of Molecular Therapy, 2013
-
Part of Cancer Research, p. 490-495, 2013
-
Islet Engraftment and Revascularization in Clinical and Experimental Transplantation
Part of Cell Transplantation, p. 243-251, 2013
-
Part of Human Gene Therapy, p. 766-775, 2013
- DOI for Tat‐PTD‐modified Oncolytic Adenovirus Driven by the SCG3 Promoter and ASH1 Enhancer for Neuroblastoma Therapy
- Download full text (pdf) of Tat‐PTD‐modified Oncolytic Adenovirus Driven by the SCG3 Promoter and ASH1 Enhancer for Neuroblastoma Therapy
-
CAR/FoxP3-engineered T regulatory cells target the CNS and suppress EAE upon intranasal delivery
Part of Journal of Neuroinflammation, p. 112, 2012
- DOI for CAR/FoxP3-engineered T regulatory cells target the CNS and suppress EAE upon intranasal delivery
- Download full text (pdf) of CAR/FoxP3-engineered T regulatory cells target the CNS and suppress EAE upon intranasal delivery
-
Part of Proceedings of the National Academy of Sciences of the United States of America, p. 15877-15881, 2012
-
Age-related somatic structural changes in the nuclear genome of human blood cells
Part of American Journal of Human Genetics, p. 217-228, 2012
-
Part of Human Gene Therapy, p. 218-230, 2012
-
Part of PLoS ONE, 2011
-
Use of Macrophages to Target Therapeutic Adenovirus to Human Prostate Tumors
Part of Cancer Research, p. 1805-1815, 2011
-
Part of Gene Therapy, p. 1052-1062, 2011
-
Part of Journal of Virology, p. 13114-13123, 2011
- DOI for Adenovirus with Hexon Tat-Protein Transduction Domain Modification Exhibits Increased Therapeutic Effect in Experimental Neuroblastoma and Neuroendocrine Tumors
- Download full text (pdf) of Adenovirus with Hexon Tat-Protein Transduction Domain Modification Exhibits Increased Therapeutic Effect in Experimental Neuroblastoma and Neuroendocrine Tumors
-
Generation of antigen-specific cytolytic T cells for prostate cancer therapy
Part of Human Gene Therapy, p. 1422-1422, 2010
-
Clinical Adenoviral Gene Therapy for Prostate Cancer
Part of Human Gene Therapy, p. 807-813, 2010
-
Part of Human Gene Therapy, p. 815-827, 2010
-
Part of PLOS ONE, 2010
-
Part of Gene Therapy, p. 752-762, 2010
-
Novel markers for enterochromaffin cells and gastrointestinal neuroendocrine carcinomas
Part of Modern Pathology, p. 261-272, 2009
-
Part of Acta Oncologica, p. 391-400, 2009
- DOI for Midgut carcinoid patients display increased numbers of regulatory T cells in peripheral blood with infiltration into tumor tissue
- Download full text (pdf) of Midgut carcinoid patients display increased numbers of regulatory T cells in peripheral blood with infiltration into tumor tissue
-
Part of The Prostate, p. 70-81, 2009
- DOI for High frequency of prostate antigen-directed T cells in cancer patients compared to healthy age-matched individuals
- Download full text (pdf) of High frequency of prostate antigen-directed T cells in cancer patients compared to healthy age-matched individuals
-
Part of Cancer Immunology and Immunotherapy, p. 399-409, 2008
-
Part of British Journal of Haematology, p. 188-199, 2008
- DOI for Strategic use of an adenoviral vector for rapid and efficient ex vivo-generation of cytomegalovirus pp65-reactive cytolytic and helper T cells
- Download full text (pdf) of Strategic use of an adenoviral vector for rapid and efficient ex vivo-generation of cytomegalovirus pp65-reactive cytolytic and helper T cells
-
Part of Journal of immunotherapy (1997), p. 34-42, 2008
-
Part of Journal of immunotherapy (1997), p. 34-42, 2008
-
Part of Cancer Gene Therapy, p. 203-213, 2008
-
Part of Cancer Gene Therapy, p. 233-240, 2007
-
Part of The Prostate, p. 389-395, 2007
- DOI for Characterization of human prostate and breast cancer cell lines for experimental T cell-based immunotherapy
- Download full text (pdf) of Characterization of human prostate and breast cancer cell lines for experimental T cell-based immunotherapy
-
A novel chromogranin-A promoter-driven oncolytic adenovirus for midgut carcinoid therapy
Part of Clinical Cancer Research, p. 2455-2462, 2007
-
Part of Cancer Gene Therapy, p. 13-20, 2006
-
Part of The Prostate, p. 831-838, 2006
-
Part of Journal of immunotherapy (1997), p. 20-27, 2005
-
Gene expression in midgut carcinoid tumors: potential targets for immunotherapy
Part of Acta Oncologica, p. 32-40, 2005
-
The immunotherapy of prostate and bladder cancer
Part of BJU International, p. 728-735, 2005
-
Gene therapy and immunotherapy of prostate cancer: adenoviral-based strategies.
Part of Acta Oncol, p. 610-27, 2005
-
Part of Journal of Immunology, p. 7200-7205, 2004
-
Generation of cytotoxic T lymphocytes specific for the prostate and breast tissue antigen TARP
Part of The Prostate, p. 161-170, 2004
-
Part of Molecular Therapy, p. 355-364, 2004
-
Part of British Journal of Haematology, p. 428-38, 2003
-
Part of Endocrinology, p. 3433-40, 2003
-
Part of Cancer Res., p. 8122-6, 2001
-
GDEP, a new gene differntially expressed in normal prostate and prostate cancer.
Part of Prostate, p. 231-41, 2001
Articles, review/survey
-
News from the T cell trogocytosis front
Part of Trends in immunology, p. 677-689, 2025
- DOI for News from the T cell trogocytosis front
- Download full text (pdf) of News from the T cell trogocytosis front
-
Of mice and lymphoid aggregates: modeling tertiary lymphoid structures in cancer
Part of Frontiers in Immunology, 2023
- DOI for Of mice and lymphoid aggregates: modeling tertiary lymphoid structures in cancer
- Download full text (pdf) of Of mice and lymphoid aggregates: modeling tertiary lymphoid structures in cancer
-
Tertiary Lymphoid Structures in the Central Nervous System: Implications for Glioblastoma
Part of Frontiers in Immunology, 2021
- DOI for Tertiary Lymphoid Structures in the Central Nervous System: Implications for Glioblastoma
- Download full text (pdf) of Tertiary Lymphoid Structures in the Central Nervous System: Implications for Glioblastoma
-
Virus-Based Immunotherapy of Glioblastoma
Part of Cancers, 2019
- DOI for Virus-Based Immunotherapy of Glioblastoma
- Download full text (pdf) of Virus-Based Immunotherapy of Glioblastoma
-
Part of Seminars in Cancer Biology, p. 23-35, 2017
- DOI for The cancer-immunity cycle as rational design for synthetic cancer drugs: Novel DC vaccines and CAR T-cells
- Download full text (pdf) of The cancer-immunity cycle as rational design for synthetic cancer drugs: Novel DC vaccines and CAR T-cells
-
Genetically engineered T cells for the treatment of cancer
Part of Journal of Internal Medicine, p. 166-181, 2013
-
Oncolytic Viruses for the Treatment of Neuroendocrine Tumors
Part of Hormone and Metabolic Research, p. 877-883, 2011
Chapters in book
-
Immunotherapy for Neuroendocrine Neoplasms
Part of Neuroendocrine Tumours, p. 665-676, Springer Nature, 2024
-
Part of Neuroendocrine Tumors, p. 248-262, S. Karger, 2015
Manuscripts (preprints)
-
Multiple viruses rely on the stress-induced protein ZC3H11A for efficient replication
2017
-
-
-
-
-
-
-
Armed CAR-T cells directed against IL13Rα2 show potent activity against glioblastoma
-
Preclinical evaluation of CAR20(NAP)-T cells for B cell lymphoma
-
Complementary-determining region clustering causes CAR-T cell dysfunction
-